Xencor Data Published in Journal of Immunology Demonstrate Selectivity of New Class of Inhibitors for Inflammatory Disease

MONROVIA, Calif.--(BUSINESS WIRE)--A first-in-class protein therapeutic drug candidate has been shown to selectively inhibit its therapeutic target, according to research conducted at Xencor and published in the August 1 print issue of the Journal of Immunology. The data provides early evidence that this new class of therapeutics may offer an alternative to non-selective therapeutics that are currently used to treat inflammatory diseases such as rheumatoid arthritis (RA). Target selectivity has the potential to significantly enhance efficacy of therapeutics while limiting their toxicity and side effects, therefore selectivity has long been the goal in the development of new therapeutics to treat inflammatory disease.

MORE ON THIS TOPIC